Vicore Pharma Holding AB

Vicore Pharma Holding AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Vicore Pharma to Attend Two Investor Conferences in London in November 2017

Wed, Nov 01, 2017 08:00 CET

Vicore Pharma will present at the Biotech and Money Inv€$tival Showcase in partnership with Jefferies and host one-to-one meetings at the Jefferies 2017 London Healthcare ConferenceVicore Pharma Holding (publ) (ticker:VICO), announced today that its CEO, Per Jansson, is scheduled to present at the Biotech and Money Inv€$tival showcase on Tuesday, November 14, 2017, at the Waldorf Hilton Hotel in London, UK at 1:45 p.m. GMT and will attend the Jefferies 2017 London Healthcare Conference, November 15-16, 2017, also at the Waldorf Hilton Hotel in London. Vicore Pharma’s CEO, Per Jansson,

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Vicore Pharma to Attend Two Investor Conferences in London in November 2017

Media